← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sigmovir Biosystems, Inc.
Rockville, MD
$15,578,330
Total funding
13
Grants
Funding over time
peak $2.5M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,578,330 · 13
By mechanism
N01$4,284,039 · 2
R44$3,476,975 · 1
R01$2,099,875 · 1
R42$1,867,924 · 1
R41$1,815,071 · 3
N43$598,871 · 1
Investigators at Sigmovir Biosystems, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of VLP vaccine for RSV$1,000,000
R44 · FY2021 · AI
Development of VLP vaccine for RSV$1,000,000
R44 · FY2019 · AI
Development of VLP vaccine for RSV$1,000,000
R44 · FY2020 · AI
Task A45: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses$984,564
N01 · FY2020 · AI
Development of VLP vaccine for RSV$933,962
R42 · FY2016 · AI
Development of VLP vaccine for RSV$933,962
R42 · FY2017 · AI
Task A88: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses$836,688
N01 · FY2023 · AI
Task A45: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses$722,205
N01 · FY2022 · AI
REAGENTS FOR IMMUNOLOGIC ANALYSIS OF COTTON RAT.$598,871
N43 · FY2024 · AI
Task A15: Cotton Rat Model for the Evaluation of RSV Vaccines and Therapeutics$591,222
N01 · FY2018 · AI
The role of TLR4 and RSV F protein in immunity to RSV$532,693
R01 · FY2011 · AI
The role of TLR4 and RSV F protein in immunity to RSV$524,620
R01 · FY2012 · AI
The role of TLR4 and RSV F protein in immunity to RSV$495,638
R01 · FY2013 · AI
Inducible HMGB1 antagonist for viral-induced acute lung injury.$488,080
R41 · FY2024 · HL
Inducible HMGB1 antagonist for viral-induced acute lung injury.$488,080
R41 · FY2023 · HL
Development of VLP vaccine for RSV$476,975
R44 · FY2020 · AI
The role of TLR4 and RSV F protein in immunity to RSV$414,971
R01 · FY2010 · AI
Task A88: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses$407,153
N01 · FY2024 · AI
Task A15: Cotton Rat Model for the Evaluation of RSV Vaccines and Therapeutics$373,053
N01 · FY2019 · AI
Task A88: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses$282,719
N01 · FY2025 · AI